Correlation of procollagen (I) with prostate specific antigen and bone scan for the diagnosis of bone metastases in patients with prostate carcinoma

Hellenic Journal of Nuclear Medicine

Volumn 7, Issue 3, 2004, Pages 162-167

  Zissimopoulos, Athanassios ^a   Stellos, Constantinos ^a   Petrakis, George ^a   Baziotis, Nikolaos ^b  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b Agios Savvas Cancer Hospital   (Greece)

Author keywords

Bone metastases; Bone scan; Procollagen (I) carboxyterminal propeptide; Prostate adenocarcinoma; Prostate specific antigen

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN TYPE 1; MEDRONATE TECHNETIUM TC 99M; PROCOLLAGEN; PROCOLLAGEN TYPE 1 CARBOXYPROPEPTIDE; PROSTATE SPECIFIC ANTIGEN; PROTEIN PRECURSOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE DEVELOPMENT; BONE MATRIX; BONE METABOLISM; BONE METASTASIS; BONE RADIOGRAPHY; BONE SCINTISCANNING; CLINICAL TRIAL; COLLAGEN SYNTHESIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; RANK SUM TEST; SENSITIVITY AND SPECIFICITY;

EID: 13244255328     PISSN: 00258024     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Eble J, Sauter G, Epstein J, et al. World Health Organization Classification of Tumours. Pathology and genetics of tumours of the urinary system and male genital organs. ISBN 92 IARC Press: Lyon 2004; 832: 2415-2419
2. Elder JS, Catalona WJ. Management of newly metastatic carcinoma of the prostate. Urol Clin N Am 1984; 11: 283-295.
3. Stoll BA. Natural history, prognosis and staging of bone metastases. In: Stoll BA, Parbho S. eds. Bone metastases monitoring and treatment. New York: Raven Press 1983; 1-4.
4. Jacobs SC. Spread of prostatic cancer to bone. Urology 1983; 21: 337-344.
5. Thompson I, Goodman P, Tangen C, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215 (abstract).
6. Smith PH, Bono A, Calais da Silva F, et al. Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A sub-analysis of EORTC trial 30853. The EORTC Urological Group. Cancer 1990; 66(Suppl 5): 1009-1016.
7. Akimoto S, Koichiro A, Shimazaki J. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer. J Clin Oncol 1996; 26: 157-163.
8. Miyamoto KK, McSherry SA, Robins SP, et al. Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma. J Urol 1994; 151: 909-913.
9. Stepan JJ, Mikulecky M, Bek V, et al. Bone alkaline phosphatase isoenzyme and urinary hydroxyproline in healthy subjects, patients with osteolytic metastasis, and patients with primary hyperparathyroidism. Neoplasma 1989; 36: 495-501.
10. Takeuchi S, Yoshida K. Assay of urinary pyridinoline and deoxypyridinoline as potential markers of the rate of bone resorption: usefulness of urinary pyridinoline and deoxypyridinoline in patients with prostate cancer with bone metastasis. Jpn J Urol 1994; 85: 1521-1527.
11. Campbell PC, Blamey RW, Woolfson AM, et al. Calcium excretion (CaE) in metastatic breast cancer. Br J Surg 1983; 70: 202.
12. Mundy AR. Urinary hydroxyproline excretion in carcinoma of the prostate. A comparison of 4 different modes of assessment and its role as a marker. Br J Urol 1979; 51: 570-574.
13. Body JJ, Delmas PD. Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia. J Clin Endocrinol Metab 1992; 74: 471-475.
14. Price PA, Parthemore JG, Deftos LJ. New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone GLA protein in the plasma of normal subjects and patients with bone disease. J Clin Invest 1980; 66: 878-883.
15. Cooper EH, Whelan P, Purves D. Bone alkaline phosphatase and prostate-specific antigen in the monitoring of prostate cancer. Prostate 1994; 25: 236-242.
16. Risteli J, Elomaa I, Niemi S, et al. Radioimmunoassay for the pyridoniline cross-linked carboxy-terminal telopeptide of type 1 collagen: a new serum marker of bone collagen degradation. Clin Chem 1993; 39: 635-640.
17. Francini G, Gonnelli S, Petrioli R, et al. Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases. Cancer Epidemiol Biomarkers Prev 1993; 2: 125-129.
18. Melkko J, Niemi S, Risteli L, et al. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 1990; 36:1328-1332.
19. Kylmala T, Tammela TL, Risteli L, et al. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer 1995; 71:1061-1064.
20. Joerring S, Jensen LT, Andersen GR, et al. Types I and III procollagen extension peptides in serum respond to fracture in humans. Arch Orthop Trauma Surg 1992; 111: 265-267.
21. Simon LS, Krane SM, Wortman PD, et al. Serum levels of type I and III procollagen fragments in Paget's disease of bone. J Clin Endocrinol Metab 1984; 58: 110-120.
22. Piovesan A, Berruti A, Osella G, et al. Serum levels of carboxyterminal propeptide of type I procollagen in cancer patients with osteoblastic and osteolytic bone metastases. Int J Biol Markers 1994; 9: 243-246.
23. Grammaticos P. Diagnostic and prognostic importance of prostate specific antigen in prostate carcinoma. Hell J Nucl Med 2004; 7:146-147
24. Greek source. 35.
25. Mundy GR. Mechanisms of osteolytic bone destruction. Bone 1991; 12(Suppl 1): S1-6.
26. Epstein S. Serum and urinary markers of bone remodeling: assessment of bone turnover. Endocr Rev 1988; 9: 437-449.
27. Garnero P, Buchs N, Zekri J, et al. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 2000; 82:858-864.
28. Nakashima J, Sumitomo M, Miyajima A, et al. The value of serum carboxyterminal propeptide of type 1 procollagen in predicting bone metastases in prostate cancer. J Urol 1997; 157: 1736-1739.
29. Koizumi M, Yamada Y, Takiguchi T, et al. Bone metabolic markers in bone metastases. J Cancer Res Clin Oncol 1995; 121: 542-548.
30. Yoshida K, Sumi S, Arai K, et al. Serum Concentration of Type I Collagen Metabolites as a Quantitative Marker of Bone Metastases in Patients with Prostate Carcinoma. Cancer 1997; 80:1760-1767.
31. Hosoya Y, Arai K, Honda M, et al. Serum levels of the carboxy-terminal propeptide of type I procollagen and the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen as markers of bone metastases in patients with prostate carcinoma. Eur Urol 1997; 31: 220-223.
32. Santi I, Monti M, Vigano A, et al. Serum levels of procollagen type I carboxyterminal extension peptide in cancer patients with bone metastases. Int J Biol Markers 1995;10: 107-112.
33. Akimoto S, Inomiya H, Furuya Y, et al. Prognostic value of the serum levels of bone formation and bone resorption markers in prostate cancer patients with bone metastasis. Eur Urol 1998; 34:142-147.
34. Li F, Iqbal J, Wassif W, et al. Carboxyterminal propeptide of type I procollagen in osteomalacia. Calcif Tissue Int 1994; 55: 90-93.
35. Masanori N, Shinshi N. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer. J Urol 2001; 166: 1106-1110.
36. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level of < 4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-2246.
37. Oesterling JE, Martin SK, Bergstralh EJ, et al. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993; 269: 57-60.
38. Partin AW, Carter HB, Chan DW, et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990; 143: 747-752.
39. McNeal JE, Bostwick DG, Kindrachuck RA, et al. Patterns of progression in prostate cancer. Lancet 1986; 1: 60-63.
40. Lorente JA, Morote J, Raventos C, et al. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. J Urol 1996; 155: 1348-1351.
41. Leo ME, Bilhartz DL, Bergstralh EJ, et al. Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status? J Urol 1991; 145: 802-806.
42. Chybowski FM, Keller JJ, Bergstralh EJ, et al. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 1991; 145: 313-318.